Sacroiliac Joint Fusion Market Growth, Trends, Industry Statistics 2022-2030

The global Sacroiliac Joint Fusion market size is expected to be worth around US$ 761.45 million by 2030, according to a new report by Vision Research Reports.

The global Sacroiliac Joint Fusion market size was valued at US$ 190.5 million in 2020 and is anticipated to grow at a CAGR of 18.5% during forecast period 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39013

Report Coverage

Report Scope Details
Market Size US$ 761.45 million by 2030
Growth Rate CAGR of 18.5% From 2021 to 2030
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Indication, Surgery Type, Product, End-user
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned SI-BONE, Inc.; SIGNUS Medizintechnik GmbH; Globus Medical; Orthofix Medical Inc.; Life Spine, Inc.; Camber Spine Technologies, LLC; CoreLink Surgical; Xtant Medical; Surgalign Spine Technologies, Inc.; Medtronic

Growth Factors

Growing technological developments, the number of minimally invasive surgical procedures, reimbursement coverage, and initiatives by key companies are some of the key drivers of this market. As per AmeriHealth Caritas, by 2020, minimally invasive sacroiliac joint fusion was covered by Medicaid programs in 44 states in the U.S. while 32 Blue Cross Blue Shield plans covered minimally invasive joint fusion by 2019. This is anticipated to increase the number of MIS sacroiliac joint fusion procedures.

The COVID-19 pandemic resulted in logistical bottlenecks, decreased sales and marketing activities, low demand, and other challenges for market participants. The major impact during the pandemic, however, was canceled or postponed elective surgeries. As many countries went under lockdown and implemented movement restrictions, the number of elective surgeries plummeted. In addition, several healthcare institutions and regulatory bodies recommended the postponement of elective surgical procedures.

By Indication Analysis

The degenerative sacroilitis segment held the largest revenue share of over 35.0% in 2020. The key factors contributing to this segment growth include a high prevalence of degenerative sacroilitis, growing awareness regarding the condition, and improving diagnostic capabilities for sacroiliac joint disorders.

The trauma segment is expected to expand at the highest CAGR of 18.7% from 2021 to 2030. Trauma indication is one of the most recently approved indications by the FDA, thus contributing to the segment growth.

By Surgery Type Analysis

The minimally invasive surgeries (MIS) segment held the largest revenue share of over 91.0% in 2020 and is estimated to expand at the fastest growth rate over the forecast period. The increasing preference for minimally invasive surgeries due to associated benefits such as smaller incisions.

According to the Washington State Health Care Authority’s 2021 report, minimally invasive SI joint fusion surgery was found to be more effective than open fusion for reducing pain. It is also associated with a shorter length of stay at the hospital.

By Product Analysis

The implants segment accounted for the largest revenue share of over 70.0% in 2020 and is projected to expand at the highest CAGR over the forecast period. The key factors contributing to the segment growth include the rising demand for safe and effective sacroiliac joint fusion systems and advancements in technology and materials used in these systems.

3D printing technology is gaining popularity in various applications of MIS such as bio modeling to optimize preoperative planning, manufacturing of implants, and hardware templates and guides.

By End-user Analysis

The hospitals segment dominated the market with a revenue share of over 45.0% in 2020. The key factors contributing to the segment growth include a higher volume of surgeries performed in hospitals and a growing preference for minimally invasive surgeries.

According to the Centers for Medicare & Medicaid Services (CMS), in March 2021, there were around 187 Medicare-certified ASCs in Washington state, 442 in Texas, 457 in Florida, 817 in California, and 368 in Georgia. In fact, as per Definitive Healthcare, LLC, there were about 9,280 active ASCs in 2019 in the U.S. These numbers are anticipated to increase over the forecast period.

By Regional Analysis

North America held the largest revenue share of over 40.0% in 2020. The growth of the regional market can be attributed to the presence of key players, advanced healthcare infrastructure, and growing reimbursement coverage. Asia Pacific is projected to expand at the fastest CAGRof 19.1% over the forecast period.

SI-BONE, Inc. reported the first iFuse procedures beyond its key markets of Europe and the U.S., in countries such as Canada, Israel, Japan, Australia, Hong Kong, New Zealand, Saudi Arabia, South Africa, and Turkey, thus expanding its regional presence.

Key Players

  • SI-BONE, Inc.
  • SIGNUS Medizintechnik GmbH
  • Globus Medical
  • Orthofix Medical Inc.
  • Life Spine, Inc.
  • Camber Spine Technologies, LLC
  • CoreLink Surgical
  • Xtant Medical
  • Surgalign Spine Technologies, Inc.
  • Medtronic

Market Segmentation

  • By Indication
    • Degenerative Sacroilitis
    • Sacral Disruption
    • Trauma
  • By Surgery Type
    • MIS
    • Open
  • By Product
    • Implants
    • Accessories
  • By End-user
    • Hospitals
    • Ambulatory Surgical Centers
    • Others (Specialty Centers, Research & Academic Institutes)
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
    • Asia Pacific
      • China
      • India
      • Japan
    • Latin America
      • Brazil
      • Mexico
    • MEA
      • South Africa
      • Saudi Arabia

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39013

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Product Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Sacroiliac Joint Fusion Market, By Indication

7.1.  Sacroiliac Joint Fusion Market, by Indication, 2021-2030

7.1.1.    Degenerative Sacroilitis

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Sacral Disruption

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Trauma

7.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Sacroiliac Joint Fusion Market, By Surgery Type

8.1.  Sacroiliac Joint Fusion Market, by Surgery Type, 2021-2030

8.1.1.    MIS

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Open

8.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Sacroiliac Joint Fusion Market, By Product

9.1.  Sacroiliac Joint Fusion Market, by Product, 2021-2030

9.1.1.    Implants

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Accessories

9.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Sacroiliac Joint Fusion Market, By End-user

10.1.        Sacroiliac Joint Fusion Market, by End-user, 2021-2030

10.1.1.  Hospitals

10.1.1.1.      Market Revenue and Forecast (2017-2030)

10.1.2.  Ambulatory Surgical Centers

10.1.2.1.      Market Revenue and Forecast (2017-2030)

10.1.3.  Others (Specialty Centers, Research & Academic Institutes)

10.1.3.1.      Market Revenue and Forecast (2017-2030)

Chapter 11.      Global Sacroiliac Joint Fusion Market, Regional Estimates and Trend Forecast

11.1.        North America

11.1.1.  Market Revenue and Forecast, by Indication (2017-2030)

11.1.2.  Market Revenue and Forecast, by Surgery Type (2017-2030)

11.1.3.  Market Revenue and Forecast, by Product (2017-2030)

11.1.4.  Market Revenue and Forecast, by End-user (2017-2030)

11.1.5.  U.S.

11.1.5.1.      Market Revenue and Forecast, by Indication (2017-2030)

11.1.5.2.      Market Revenue and Forecast, by Surgery Type (2017-2030)

11.1.5.3.      Market Revenue and Forecast, by Product (2017-2030)

11.1.5.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.1.6.  Rest of North America

11.1.6.1.      Market Revenue and Forecast, by Indication (2017-2030)

11.1.6.2.      Market Revenue and Forecast, by Surgery Type (2017-2030)

11.1.6.3.      Market Revenue and Forecast, by Product (2017-2030)

11.1.6.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.2.        Europe

11.2.1.  Market Revenue and Forecast, by Indication (2017-2030)

11.2.2.  Market Revenue and Forecast, by Surgery Type (2017-2030)

11.2.3.  Market Revenue and Forecast, by Product (2017-2030)

11.2.4.  Market Revenue and Forecast, by End-user (2017-2030)

11.2.5.  UK

11.2.5.1.      Market Revenue and Forecast, by Indication (2017-2030)

11.2.5.2.      Market Revenue and Forecast, by Surgery Type (2017-2030)

11.2.5.3.      Market Revenue and Forecast, by Product (2017-2030)

11.2.5.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.2.6.  Germany

11.2.6.1.      Market Revenue and Forecast, by Indication (2017-2030)

11.2.6.2.      Market Revenue and Forecast, by Surgery Type (2017-2030)

11.2.6.3.      Market Revenue and Forecast, by Product (2017-2030)

11.2.6.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.2.7.  France

11.2.7.1.      Market Revenue and Forecast, by Indication (2017-2030)

11.2.7.2.      Market Revenue and Forecast, by Surgery Type (2017-2030)

11.2.7.3.      Market Revenue and Forecast, by Product (2017-2030)

11.2.7.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.2.8.  Rest of Europe

11.2.8.1.      Market Revenue and Forecast, by Indication (2017-2030)

11.2.8.2.      Market Revenue and Forecast, by Surgery Type (2017-2030)

11.2.8.3.      Market Revenue and Forecast, by Product (2017-2030)

11.2.8.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.3.        APAC

11.3.1.  Market Revenue and Forecast, by Indication (2017-2030)

11.3.2.  Market Revenue and Forecast, by Surgery Type (2017-2030)

11.3.3.  Market Revenue and Forecast, by Product (2017-2030)

11.3.4.  Market Revenue and Forecast, by End-user (2017-2030)

11.3.5.  India

11.3.5.1.      Market Revenue and Forecast, by Indication (2017-2030)

11.3.5.2.      Market Revenue and Forecast, by Surgery Type (2017-2030)

11.3.5.3.      Market Revenue and Forecast, by Product (2017-2030)

11.3.5.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.3.6.  China

11.3.6.1.      Market Revenue and Forecast, by Indication (2017-2030)

11.3.6.2.      Market Revenue and Forecast, by Surgery Type (2017-2030)

11.3.6.3.      Market Revenue and Forecast, by Product (2017-2030)

11.3.6.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.3.7.  Japan

11.3.7.1.      Market Revenue and Forecast, by Indication (2017-2030)

11.3.7.2.      Market Revenue and Forecast, by Surgery Type (2017-2030)

11.3.7.3.      Market Revenue and Forecast, by Product (2017-2030)

11.3.7.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.3.8.  Rest of APAC

11.3.8.1.      Market Revenue and Forecast, by Indication (2017-2030)

11.3.8.2.      Market Revenue and Forecast, by Surgery Type (2017-2030)

11.3.8.3.      Market Revenue and Forecast, by Product (2017-2030)

11.3.8.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.4.        MEA

11.4.1.  Market Revenue and Forecast, by Indication (2017-2030)

11.4.2.  Market Revenue and Forecast, by Surgery Type (2017-2030)

11.4.3.  Market Revenue and Forecast, by Product (2017-2030)

11.4.4.  Market Revenue and Forecast, by End-user (2017-2030)

11.4.5.  GCC

11.4.5.1.      Market Revenue and Forecast, by Indication (2017-2030)

11.4.5.2.      Market Revenue and Forecast, by Surgery Type (2017-2030)

11.4.5.3.      Market Revenue and Forecast, by Product (2017-2030)

11.4.5.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.4.6.  North Africa

11.4.6.1.      Market Revenue and Forecast, by Indication (2017-2030)

11.4.6.2.      Market Revenue and Forecast, by Surgery Type (2017-2030)

11.4.6.3.      Market Revenue and Forecast, by Product (2017-2030)

11.4.6.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.4.7.  South Africa

11.4.7.1.      Market Revenue and Forecast, by Indication (2017-2030)

11.4.7.2.      Market Revenue and Forecast, by Surgery Type (2017-2030)

11.4.7.3.      Market Revenue and Forecast, by Product (2017-2030)

11.4.7.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.4.8.  Rest of MEA

11.4.8.1.      Market Revenue and Forecast, by Indication (2017-2030)

11.4.8.2.      Market Revenue and Forecast, by Surgery Type (2017-2030)

11.4.8.3.      Market Revenue and Forecast, by Product (2017-2030)

11.4.8.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.5.        Latin America

11.5.1.  Market Revenue and Forecast, by Indication (2017-2030)

11.5.2.  Market Revenue and Forecast, by Surgery Type (2017-2030)

11.5.3.  Market Revenue and Forecast, by Product (2017-2030)

11.5.4.  Market Revenue and Forecast, by End-user (2017-2030)

11.5.5.  Brazil

11.5.5.1.      Market Revenue and Forecast, by Indication (2017-2030)

11.5.5.2.      Market Revenue and Forecast, by Surgery Type (2017-2030)

11.5.5.3.      Market Revenue and Forecast, by Product (2017-2030)

11.5.5.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.5.6.  Rest of LATAM

11.5.6.1.      Market Revenue and Forecast, by Indication (2017-2030)

11.5.6.2.      Market Revenue and Forecast, by Surgery Type (2017-2030)

11.5.6.3.      Market Revenue and Forecast, by Product (2017-2030)

11.5.6.4.      Market Revenue and Forecast, by End-user (2017-2030)

Chapter 12.  Company Profiles

12.1.              SI-BONE, Inc.

12.1.1.  Company Overview

12.1.2.  Indication Offerings

12.1.3.  Financial Performance

12.1.4.  Recent Initiatives

12.2.              SIGNUS Medizintechnik GmbH

12.2.1.  Company Overview

12.2.2.  Indication Offerings

12.2.3.  Financial Performance

12.2.4.  Recent Initiatives

12.3.              Globus Medical

12.3.1.  Company Overview

12.3.2.  Indication Offerings

12.3.3.  Financial Performance

12.3.4.  Recent Initiatives

12.4.              Orthofix Medical Inc.

12.4.1.  Company Overview

12.4.2.  Indication Offerings

12.4.3.  Financial Performance

12.4.4.  Recent Initiatives

12.5.              Life Spine, Inc.

12.5.1.  Company Overview

12.5.2.  Indication Offerings

12.5.3.  Financial Performance

12.5.4.  Recent Initiatives

12.6.              Camber Spine Technologies, LLC

12.6.1.  Company Overview

12.6.2.  Indication Offerings

12.6.3.  Financial Performance

12.6.4.  Recent Initiatives

12.7.              CoreLink Surgical

12.7.1.  Company Overview

12.7.2.  Indication Offerings

12.7.3.  Financial Performance

12.7.4.  Recent Initiatives

12.8.              Xtant Medical

12.8.1.  Company Overview

12.8.2.  Indication Offerings

12.8.3.  Financial Performance

12.8.4.  Recent Initiatives

12.9.              Surgalign Spine Technologies, Inc.

12.9.1.  Company Overview

12.9.2.  Indication Offerings

12.9.3.  Financial Performance

12.9.4.  Recent Initiatives

12.10.           Medtronic

12.10.1.               Company Overview

12.10.2.               Indication Offerings

12.10.3.               Financial Performance

12.10.4.               Recent Initiatives

Chapter 13.  Research Methodology

13.1.              Primary Research

13.2.              Secondary Research

13.3.              Assumptions

Chapter 14.  Appendix

14.1.              About Us

Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39013

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com